Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1999 1
2003 1
2005 1
2006 1
2008 1
2009 3
2010 1
2011 1
2012 6
2013 3
2014 7
2015 4
2016 10
2017 9
2018 14
2019 12
2020 19
2021 10
2022 8
2023 8
2024 10
2025 20
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
ctDNA or Merkel Virus Antibodies for Surveillance of Merkel Cell Carcinoma Recurrence.
Thakuria M, Akaike T, Silk AW, Hippe DS, Ch'en PY, Alam R, Chan JE, Park SY, Khaddour K, Biese KB, Jabbour AJ, Fu A, Gilmour MW, Finberg A, Chiu MW, Kim H, Urman NM, Hall ET, Bhatia S, Nghiem P, Zaba LC. Thakuria M, et al. Among authors: bhatia s. JAMA Dermatol. 2026 Jul 8:e262153. doi: 10.1001/jamadermatol.2026.2153. Online ahead of print. JAMA Dermatol. 2026. PMID: 42418167
IMPORTANCE: Merkel cell carcinoma (MCC) is associated with a high recurrence rate of 40%. It is important to know which of 2 blood-based tumor biomarkers available for use in clinical practice is more accurate in detecting MCC recurrence. ...DESIGN, SETTING, AND PARTICIPAN …
IMPORTANCE: Merkel cell carcinoma (MCC) is associated with a high recurrence rate of 40%. It is important to know which of 2 blood-ba …
Fructose-1,6-Bisphosphatase 1 Deficiency.
Bijarnia-Mahay S, Bhatia S, Arora V. Bijarnia-Mahay S, et al. Among authors: bhatia s. 2019 Dec 5 [updated 2026 Jul 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. 2019 Dec 5 [updated 2026 Jul 7]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. PMID: 31804789 Free Books & Documents. Review.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chen D, Chmielowski B, Choi J, DiMaio D, Dronca R, Fleming MD, Galan A, Guild S, Hu-Lieskovan S, Karakousis G, Kendra K, Kiuru M, Lange JR, Lanning R, Logan T, Materin M, Nelson K, Olson D, Olszanski AJ, Ott PA, Puzanov I, Rothermel L, Salama AK, Shannon A, Sharma R, Singh A, Stacey A, Tsai K, Wuthrick E, Xing Y, McMillian N, Espinosa S. Swetter SM, et al. Among authors: bhatia s. J Natl Compr Canc Netw. 2026 Jun;24(6):272-277. doi: 10.6004/jnccn.2026.0027. J Natl Compr Canc Netw. 2026. PMID: 42297031
The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly inf …
The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous …
Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy.
Senthilkumar MB, Sharma S, Srinivasan N, Varghese A, Sarangi P, Singh V, Kumar N, Yenurkar D, Mukherjee S, Amit S, Bhatia S, Misra SK, Puri RD, Chamberlain J, Jayandharan GR. Senthilkumar MB, et al. Among authors: bhatia s. J Cell Mol Med. 2026 Mar;30(5):e71078. doi: 10.1111/jcmm.71078. J Cell Mol Med. 2026. PMID: 41793215 Free PMC article.
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.
Flores TF, Tonorezos ES, Bhatia S, Brahmer JR, Cappelli LC, Cooper M, Davies M, Guild S, Gunturu K, Haanen JBAG, Johnson DB, Lacouture ME, Leidner R, Mitchell S, Moledina DG, Moslehi J, Naidoo J, Obeid M, Postow M, Puzanov I, Reid ME, Santomasso BD, Schadendorf D, Silk AW, Sullivan RJ, Walunas T, Wang Y, Ascierto PA, Ernstoff MS. Flores TF, et al. Among authors: bhatia s. J Immunother Cancer. 2026 Mar 3;14(3):e012823. doi: 10.1136/jitc-2025-012823. J Immunother Cancer. 2026. PMID: 41775429 Free PMC article. Review.
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran S, Warner AB, Zager JS, Chmielowski B, Patel SP, Hernandez-Aya LF, Correa ZM, Fecher LA, Najjar YG, Montazeri K, Shoushtari AN, Javed A, Gombos DS, Salama AKS, Tsai K, Miller FH, Khushalani N, Seedor RS, Lipson EJ, Reddy SA, Buchbinder E, Bhatia S, Pavlick A, Mehmi I, Aaberg T, Ikeguchi AP, Kim IK, Walter SD, Singh AD, Sullivan RJ, Choi JS, Williams BK Jr, Orloff M, Mruthyunjaya P, Schollenberger MD, Gandhi N, Harbour JW, Chandra S. Alban J, et al. Among authors: bhatia s. Cancers (Basel). 2025 Dec 30;18(1):121. doi: 10.3390/cancers18010121. Cancers (Basel). 2025. PMID: 41514630 Free PMC article.
BACKGROUND/OBJECTIVES: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, most commonly to the liver, despite effective local treatment. ...CONCLUSIONS: This is the first study to provide consensus-based guidance inc …
BACKGROUND/OBJECTIVES: Uveal melanoma is a rare but aggressive intraocular malignancy that metastasizes in up to half of patients, mo …
Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.
Yamada MM, Chandrasekhar S, Gooley TA, Chen RE, Doolittle-Amieva C, Ansstas G, Bhatia S, Hall ET, Nghiem PT, Park SY, Chen DY. Yamada MM, et al. Among authors: bhatia s. J Immunother Cancer. 2025 Dec 25;13(12):e013564. doi: 10.1136/jitc-2025-013564. J Immunother Cancer. 2025. PMID: 41448830 Free PMC article.
BACKGROUND: Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness remains limited. . …
BACKGROUND: Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metasta …
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management.
Akaike T, Thakuria M, Silk AW, Hippe DS, Ch'en PY, Park SY, Urman NM, Chiu MW, Kim H, Kim EY, Hall ET, Bhatia S, Reddy S, Krainock M, Aleshin A, Choi JS, Tsai KY, Yom SS, Yu SS, Choi J, Chandra S, Nghiem PT, Zaba LC. Akaike T, et al. Among authors: bhatia s. J Am Acad Dermatol. 2026 Feb;94(2):548-556. doi: 10.1016/j.jaad.2025.10.032. Epub 2025 Oct 10. J Am Acad Dermatol. 2026. PMID: 41077138 Free PMC article.
BACKGROUND: Merkel cell carcinoma (MCC) recurs in 40% of patients. Circulating tumor DNA (ctDNA) is an emerging blood-based biomarker for early MCC recurrence detection. ...
BACKGROUND: Merkel cell carcinoma (MCC) recurs in 40% of patients. Circulating tumor DNA (ctDNA) is an emerging blood-based biomarker …
143 results